6 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heartcardiovascular disorder, heart disorder, heart failureRecruitingPhase 32026-10-01NCT06935370
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failurecardiovascular disorder, heart disorder, heart failureRecruitingPhase 32026-10-01NCT06424288
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country StudyDisease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Rare Diseases, Urogenital Diseases, glomerulonephritis, kidney disorder, nephritis, urinary system disorderRecruitingPhase 42026-09-09NCT07746895
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingAdnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorderActive, not recruitingPhase 32026-06-22NCT05059522
Achieving a Better Outcome Through Limiting the Glioblastoma Clinical Target VolumeNeoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, injury, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor, radiation injuryRecruitingNot applicable2026-02-27NCT06719440
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerMetastatic HER2-positive Breast CancerRecruitingPhase 32026-02-10NCT06435429